相关实验视频

Updated: Jan 15, 2026

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

基于结构的虚拟查发现了SOS1的新兴抑制剂

Silvia Bonomo¹, Floriane Gibault¹, Sharan K Bagal²

¹Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

ACS medicinal chemistry letters

|October 15, 2025

概括

研究人员发现了抑制SOS1的新型化合物,SOS1是KRAS的关键调节者. 这一发现为向癌症中异常KRAS激活提供了一个新的策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

克拉斯激活是由SOS1调节的,它催化了GTP-to-GDP的营业额.
不正常的KRAS激活驱动了几种类型的癌症.
抑制SOS1::KRAS相互作用是一种有前途的抗癌策略.

研究的目的:

为了确定SOS1的新型抑制剂1.
将SOS1的结合剂转化为功能抑制剂.

主要方法:

虚拟选AstraZeneca的化合物集合.
识别21至26之间重原子数的化合物.
基于结构和知识的药物设计.

主要成果:

确定了两个SOS1的新型和高效的结合剂.
这些结合剂符合已知的化合物的最小药理要求.
这些结合剂被开发成功能性的SOS1抑制剂.

结论:

通过虚拟查发现了新的SOS1抑制剂.
这些抑制剂代表了KRAS驱动的恶性瘤的潜在治疗策略.
进一步的发展对癌症治疗有希望.

关键词:

克拉斯 (Kras) 是一个国家.这是一种SOS1抑制剂.虚拟选是一个虚拟的选.

更多相关视频

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods

Published on: December 21, 2019

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...